BioLargo, Inc. Files 8-K Report
Ticker: BLGO · Form: 8-K · Filed: Aug 15, 2025 · CIK: 880242
Sentiment: neutral
Topics: 8-k, disclosure, financials
TL;DR
BioLargo filed an 8-K. Check for financial updates and disclosures.
AI Summary
On August 15, 2025, BioLargo, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and the submission of financial statements and exhibits. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing indicates BioLargo, Inc. is complying with regulatory requirements for reporting financial information and disclosures. Investors should review the full filing for details on the company's financial status and any material updates.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate negative or positive material events.
Key Players & Entities
- BIOLARGO, INC. (company) — Registrant
- August 15, 2025 (date) — Date of Report
- 14921 Chestnut St. (address) — Principal Executive Offices
- Westminster, California (location) — Principal Executive Offices
- 92683 (zip_code) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by BioLargo, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is August 15, 2025.
What is BioLargo, Inc.'s principal executive office address?
BioLargo, Inc.'s principal executive office is located at 14921 Chestnut St., Westminster, California 92683.
What is BioLargo, Inc.'s IRS Employer Identification Number?
BioLargo, Inc.'s IRS Employer Identification Number is 65-0159115.
What state is BioLargo, Inc. incorporated in?
BioLargo, Inc. is incorporated in Delaware.
Filing Stats: 585 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-08-15 11:50:21
Filing Documents
- blgo20250815_8k.htm (8-K) — 27KB
- ex_853909.htm (EX-99.1) — 9KB
- slide01.jpg (GRAPHIC) — 115KB
- slide02.jpg (GRAPHIC) — 207KB
- slide03.jpg (GRAPHIC) — 122KB
- slide04.jpg (GRAPHIC) — 134KB
- slide05.jpg (GRAPHIC) — 120KB
- slide06.jpg (GRAPHIC) — 183KB
- slide07.jpg (GRAPHIC) — 82KB
- slide08.jpg (GRAPHIC) — 97KB
- slide09.jpg (GRAPHIC) — 189KB
- slide10.jpg (GRAPHIC) — 43KB
- slide11.jpg (GRAPHIC) — 231KB
- slide12.jpg (GRAPHIC) — 178KB
- slide13.jpg (GRAPHIC) — 200KB
- slide14.jpg (GRAPHIC) — 147KB
- slide15.jpg (GRAPHIC) — 174KB
- 0001437749-25-027100.txt ( ) — 3219KB
- blgo-20250815.xsd (EX-101.SCH) — 3KB
- blgo-20250815_def.xml (EX-101.DEF) — 11KB
- blgo-20250815_lab.xml (EX-101.LAB) — 14KB
- blgo-20250815_pre.xml (EX-101.PRE) — 11KB
- blgo20250815_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. BioLargo, Inc., presented the slides attached as Exhibit 99.1 , which are incorporated herein by reference, at a webcast investor conference held on August 15, 2025 at 8:00 AM Pacific Time. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01, and in the slide presentation attached as Exhibit 99.1 to this Current Report, shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the information under the heading "Safe Harbor Act" in the exhibits attached hereto.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Slide deck presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 15, 2025 BIOLARGO, INC. By: /s/ Dennis P. Calvert Dennis P. Calvert President and Chief Executive Officer